What did the Veradermics VDPHL01 Phase 3 hair-loss results actually show?

The short answer

On 19 October 2026 Veradermics reported positive Phase 3 results for VDPHL01 in 536 men with mild-to-moderate pattern hair loss. Both doses beat placebo decisively on hair count: 28.6 hairs/cm² (once daily) and 36.4 hairs/cm² (twice daily) versus 6.6 for placebo at six months, p<0.0001 (company release, NCT06972264).

The part most of the coverage buried: VDPHL01 is minoxidil. Not a new molecule, not a new mechanism. It is an extended-release oral tablet of a drug that has been on the market since the 1980s and that dermatologists already prescribe off-label every day.

That makes this less exciting than "new hair-loss drug" and considerably more interesting. It is a worked example of what happens when someone takes a widely-used off-label treatment and actually runs the registration trials — which is precisely the thing that has never happened for any of the peptides people ask us about for hair.

Evidence tier: 2. Large randomised placebo-controlled trial, but reported via company press release. No peer-reviewed publication, no full dataset, six months of controlled data only. Educational content, not medical advice.

Key points:

• 536 men, randomised to VDPHL01 8.5 mg once daily, 8.5 mg twice daily, or placebo.
• Hair count beat placebo by roughly 22–30 hairs/cm². Placebo itself gained 6.6.
• Separation from placebo by Month 2, the earliest point measured.
• No treatment-related serious adverse events and no cardiac adverse events of special interest.
• Side effects are the ones minoxidil always had: peripheral edema and hair growing where you
• It is minoxidil in a new formulation, not a new drug, and it is not approved.

What they actually measured

Two co-primary endpoints at Month 6, both pre-specified: change in non-vellus target area hair count, and the proportion of men reporting "improved" or "much improved" coverage on the Androgenetic Alopecia Impact Rating Scale.

All active-arm comparisons p<0.0001.

A second trial, Study 302 (NCT06724614, 519 men, reported April 2026), produced closely matching numbers: 30.3 and 33.0 hairs/cm² against 7.3 for placebo. Two independent trials landing within a few hairs of each other is the most convincing thing in this release — far more than either result alone.

A lesson hiding in those two percentage rows

Notice that the same trial supports both "85% of men saw improvement" and "69% of men saw improvement". Neither is wrong. The first counts anyone reporting any improvement; the second counts only those reporting "improved" or "much improved", which was the pre-specified endpoint.

Headlines will use 85%. The regulator will use 69%. When you see a response rate quoted anywhere, the question is always which threshold it used — and whether that threshold was chosen before or after the data came in. Here it was chosen before, which is the right way round.

The thing almost nobody is saying: this is minoxidil

VDPHL01 is an extended-release oral formulation of minoxidil at 8.5 mg. The company is explicit about this. The formulation uses a gel matrix to avoid the high peak concentrations of immediate-release oral minoxidil while keeping levels above the threshold for hair growth longer.

Low-dose oral minoxidil is already prescribed off-label for hair loss, widely, by dermatologists. So what is genuinely new here is not the drug. It is:

1. A formulation designed to cut the cardiovascular peak, which is the actual reason oral
2. Registration trials. Over 1,600 participants across three studies, placebo-controlled,

That second point is the whole story. Off-label use means every prescriber improvises the dose and nobody collects the safety data systematically. Running the trials converts an informal practice into a labelled one with known numbers. There has been no new FDA-approved prescription medicine for pattern hair loss in nearly 30 years.

What the safety data does and does not cover

Both are classic minoxidil effects and both are clearly dose-related. Hypertrichosis — hair growing on the face, arms, elsewhere — at 9% on the twice-daily dose is not a trivial number for a cosmetic treatment, and it is the trade-off against that arm's better hair count. The earlier Study 302 saw more edema (5.3% and 6.3%) and less hypertrichosis.

No treatment-related serious adverse events, and no cardiac adverse events of special interest. That is genuinely reassuring and it is also six months of data. Pattern hair loss treatment is taken for decades. Six months of cardiac safety in men with mild-to-moderate hair loss does not establish what happens at year five, and the company does not claim it does — 12-month data from Study 302 is expected later this year.

Three further caveats worth holding

This is a press release, not a paper. Topline company announcements present the data the company chooses, in the framing it chooses. The full dataset, the dropout handling, the subgroup behaviour and the peer review are all still to come.

The placebo arm gained 6.6 hairs/cm². Men who took nothing grew measurably more hair over six months. That is a useful reminder of how much apparent improvement comes from measurement variation, regression to the mean, and simply being in a trial where someone counts carefully.

"Mild-to-moderate" is doing work. These men were not advanced cases. Results in that group do not transfer automatically to someone with extensive loss.

Why this is on a peptide site

Because people keep asking us which peptide regrows hair, and the honest answer is none of them. GHK-Cu turns up constantly in that context; its best evidence is topical and cosmetic, and hair loss is itself among the side effects posters report with it. There is no peptide on this site with randomised human evidence for pattern hair loss.

VDPHL01 is a useful contrast rather than a competitor. Two trials, 1,055 men between them, placebo-controlled, pre-specified endpoints, published safety tables with denominators, an identified failure mode, and a regulator who will say yes or no in public. That is what an evidence base looks like. Set it next to a compound whose support is a handful of enthusiastic posts and the gap stops being abstract.

What happens next

• 12-month data from Study 302 Part B, expected later in 2026 — the first look past six months.
• Study 306 (NCT07146022), 556 women on 4.5 mg,
• An FDA filing, on a timeline the company has not stated publicly.

Limitations

This is educational content, not medical advice, and nothing here is a recommendation to take minoxidil in any form.

• Topline press-release data. Not peer-reviewed, no full dataset available.
• Six months of placebo-controlled data for a treatment taken indefinitely.
• Men with mild-to-moderate pattern hair loss only; female data does not exist yet.
• We have not independently analysed the data and cannot.
• Oral minoxidil is a prescription decision with cardiovascular considerations. That conversation

The bottom line

A well-run pair of trials showed that an extended-release oral minoxidil grows meaningfully more hair than placebo in men, fast, with side effects that are predictable, dose-related and mostly cosmetic. If approved it would be the first new prescription option for pattern hair loss in roughly three decades, which matters for a condition affecting 50 million men in the US alone.

It is also still minoxidil, still six months of data, still a press release, and still not approved. All of those can be true at once — and the reason this result is worth paying attention to is not that the molecule is exciting. It is that somebody finally did the work of proving what a commonly used drug does, in public, with a control group.

Related on this site

• Oral minoxidil: what the evidence actually supports
• Are peptides safe for older adults?
• Our evidence-tier framework
• GHK-Cu beyond skincare
• The peptide drug pipeline
• Spotting counterfeit peptides

References

• Veradermics, Inc. "Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 '304' Clinical Trial in Male Pattern Hair Loss." Business Wire, 19 October 2026. Release
• Study '304' — Phase 3, VDPHL01 8.5 mg QD and BID in 536 men. NCT06972264
• Study '302' — Phase 2/3, VDPHL01 8.5 mg QD and BID in 519 men; Part A topline reported April 2026. NCT06724614
• Study '306' — Phase 2/3, VDPHL01 4.5 mg QD and BID in 556 women; topline expected H1 2027. NCT07146022